Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report.
Celesia
Benedetto M
BM
Onorante
Anna
A
Nunnari
Giuseppe
G
Mughini
Maria T
MT
Mavilla
Sergio
S
Massimino
Santa D
SD
Russo
Rosario
R
D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015497:HIV-1; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use; D017119:Porphyria Cutanea Tarda / Q000139:chemically induced* / Q000821:virology; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D011753:Pyrones / Q000009:adverse effects* / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019438:Ritonavir / Q000009:adverse effects / Q000627:therapeutic use; D013449:Sulfonamides; D000068698:Tenofovir
D017320:HIV Protease Inhibitors; D063065:Organophosphonates; D011725:Pyridines; D011753:Pyrones; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; D019259:Lamivudine; D000068698:Tenofovir; D000225:Adenine; D019438:Ritonavir; C107201:tipranavir